secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2026-08-06T20:32:33+00:00
Accession:  0001079973-26-001006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Starling Oncology Q2 revenue up 34.6% to $161.3M; raises FY2026 guidance
------------------------------------------------------------------------

- Revenue $161.3M (+34.6% YoY); gross profit $27.2M (+55.2%).
- Net loss narrowed to $9.8M from $17.0M; EPS $(0.08) vs $(0.15).
- Adjusted EBITDA turned positive at $229K vs $(4.1M) loss in prior year.
- Specialty Pharmacy revenue up 58% YoY; added ~230,000 capitated lives in California.
- Raised full-year 2026 revenue and gross profit guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/0001079973-26-001006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/stln_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-001006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer